This article is based on a poster originally authored by An Ouyang, Spencer Chiang and Chao Wang. Antibody-drug conjugates (ADCs) are a new class of anti-cancer therapeutics that are both novel and ...

Discover the top 3 manufacturing mistakes CDMOs make and how to prevent them when scaling for next-generation oncology.

Given the multifaceted nature of ADCs, developers should have an integrated analytical toolkit. Three complementary approaches dominate the current landscape: Ligand Binding Assays (LBA): Ideal for ...

One of the fastest-growing segments of pharmaceuticals, as highlighted at the 2024 J.P. Morgan Healthcare Conference, is the antibody-drug conjugate (ADC) segment. ADCs consist of four main elements: ...

Unchained Labs, the life sciences company that's all about getting biologics and gene therapy researchers the right tool for the job, just launched a brand-new application on Stunner today that ...

This novel approach utilizes cysteine-engineered antibodies which allows for the development of uniform and homogenous ADCs with precise control of the drug to antibody ratio (DAR). The drug-payload, ...

In 1910, German scientist Paul Ehrlich introduced a groundbreaking concept to the world: chemical compounds could be engineered to interact with unique receptors on disease-causing cells while ...

The concept of an antibody drug conjugate, or ADC, is straightforward: a cancer-killing drug is chemically linked to an antibody that targets the delivery of the therapy to a tumor. This drug class ...

PRINCETON, N.J., Feb. 19, 2025 (GLOBE NEWSWIRE) -- Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company developing targeted immunotherapeutic drugs, today announced its plans to ...

Presentations to highlight preclinical data supporting the clear differentiation of Adcentrx's clinical-stage ADRX-0405 STEAP1 ADC and preclinical ADRX-0134 NaPi2b ADC Adcentrx to present new ...